Lake Street Capital Markets LLC
07/30/2026 | Press release | Distributed by Public on 07/30/2026 09:05
AEON Biopharma, Inc. (AEON) - Initiation of Coverage
Lake Street Capital Markets Analyst, Thomas Flaten, initiated coverage of AEON Biopharma, Inc. with a BUY rating and price target of $1 (AEON-$1). AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!
NameEmail Address
Thanks for joining our mailing list.
Oops! Something went wrong while submitting the form.
Lake Street Capital Markets LLC published this content on July 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 30, 2026 at 15:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]